Eli Lilly
Trade Eli Lilly 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About LLY
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies.
LLY Key Statistics
Stock Snapshot
With a market cap of 1.32T, Eli Lilly(LLY) trades at $1,406.00. The stock has a price-to-earnings ratio of 47.03 and currently yields dividends of 0.47%.
During the trading session on 2026-11-17, Eli Lilly(LLY) shares reached a daily high of $1,432.28 and a low of $1,401.66. At a current price of $1,406.00, the stock is +0.3% higher than the low and still -1.8% under the high.
Trading volume for Eli Lilly(LLY) stock has reached 1.51M, versus its average volume of 3.18M.
Over the past 52 weeks, Eli Lilly(LLY) stock has traded between a high of $1,475.25 and a low of $850.51.
Over the past 52 weeks, Eli Lilly(LLY) stock has traded between a high of $1,475.25 and a low of $850.51.
LLY News
Rhythm Pharmaceuticals (RYTM) rose 5.4% amid a report that Eli Lilly (LLY) is evaluating two possible takeover targets in the obesity market, including Rhythm a...
Eli Lilly and Co. (NYSE:LLY) entered a strategic research collaboration and licensing agreement with privately held biotechnology company Stipple Bio Inc. on Mo...
Eli Lilly (LLY) has signed an exclusive global licensing agreement with Cambridge, Massachusetts-based biotech firm Stipple Bio to discover and commercialize ca...
Analyst ratings
81%
of 32 ratingsMore LLY News
Eli Lilly And Company (LLY) announced an update on their ongoing clinical study. Study Overview: Eli Lilly’s NCT07900633 study is officially titled “A Phase 3,...
Eli Lilly And Company (LLY) announced an update on their ongoing clinical study. Study Overview: Eli Lilly’s Phase 1 study, officially titled "A Phase 1, Open-...
Eli Lilly And Company (LLY) announced an update on their ongoing clinical study. Study Overview: Eli Lilly and Company (LLY) has updated a Phase 1 study titled...
BMO Capital analyst Evan Seigerman maintained a Buy rating on Eli Lilly & Co yesterday and set a price target of $1,650.00. Evan Seigerman’s rating is based on...
Eli Lilly (NYSE:LLY) agreed to acquire privately held Calytrix Bio in a deal valued at up to US$1.5b. The transaction brings Calytrix Bio's rare blood cancer p...
The past decade has been eventful for Eli Lilly (LLY +0.05%). The company made significant breakthroughs in diabetes and weight loss, which helped drive its mar...
Eli Lilly (LLY) is acquiring privately held Calytrix Bio in a deal that’s valued at up to $1.5 billion....
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.